What is the catalog number for Buparlisib?

The catalog number for Buparlisib is HY-70063.

What sizes are available for Buparlisib?

Buparlisib is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg.

How many pack sizes does Buparlisib come in?

Buparlisib is available in 7 different pack sizes.

Is Buparlisib in stock?

Buparlisib is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Buparlisib?

Buparlisib is manufactured by QuantiMol.

What is the estimated delivery time for Buparlisib?

Estimated delivery time for Buparlisib is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Buparlisib?

The safety data sheet for Buparlisib is available here: http://file.medchemexpress.com/batch_PDF/HY-70063/Buparlisib-SDS-MedChemExpress.pdf.

Is this product animal-origin-free?

Animal-origin-free status, where applicable, is noted on the datasheet under formulation details.

Does this product need any special customs documentation to be imported to my country?

If you’re outside the EU, UK, or USA, you’re responsible for customs clearance and any related taxes or fees. We provide the standard import documents, such as the Commercial Invoice, Packing List, and Airway Bill, in advance, so let us know early if your customs office needs anything additional for this specific product.

What buffer is this product supplied in?

The formulation or storage buffer is listed on the product datasheet. If you require a carrier-free or custom formulation, contact us before ordering, as this may involve a made-to-order production timeline.

Buparlisib

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.

Product Specifications

CAS Number

944396-07-0

Product Name Alternative

BKM120; NVP-BKM120

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; PI3K

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NVP-BKM120.html

Concentration

10mM

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F

Molecular Formula

C18H21F3N6O2

Molecular Weight

410.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Burger MT, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011 Aug 26;2 (10) :774-9.|[2]Zheng Y, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity. J Mol Med (Berl) . 2012 Jun;90 (6) :695-706.|[3]Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22 (7) :723-6.|[4]Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.